20-F: Ascendis Pharma Reports Strong Revenue Growth, Expands Portfolio

Ascendis Pharma A/S reported significant revenue growth in 2025, driven by strong global sales of YORVIPATH and SKYTROFA, while advancing its rare disease and oncology pipelines.

Summary

• Revenue for the year ended December 31, 2025, increased to 720.1 million EUR, up 356.5 million EUR from 2024.
• Commercial product sales reached 683.6 million EUR in 2025, a substantial increase of 457.8 million EUR from 2024.
• YORVIPATH sales contributed 477.4 million EUR in 2025, a significant rise from 28.7 million EUR in 2024, following its commercial availability in the U.S. since December 2024 and Japan since November 2025.
• SKYTROFA sales grew to 206.2 million EUR in 2025, up from 197.0 million EUR in 2024.
• Net loss improved to 228.0 million EUR in 2025, compared to 378.1 million EUR in 2024.
• Cash flows from operating activities turned positive at 53.9 million EUR in 2025, an improvement of 360.1 million EUR from the previous year.
• The company's total equity presented a deficit of 162.8 million EUR as of December 31, 2025, compared to a deficit of 105.7 million EUR in 2024.
• A non-cash gain of 35.7 million EUR was recognized in 2025 related to VISEN Pharmaceuticals' Initial Public Offering (IPO) on the Hong Kong Stock Exchange in March 2025.
• The company entered into a new lease agreement for its Hellerup, Denmark headquarters, effective July 1, 2025, replacing previous leases at the same property, with a non-terminable period until July 1, 2040, for the landlord and July 1, 2035, for the tenant.
• The new lease covers expanded premises, including additional areas taken over as of January 15 and April 1, 2025.
• Estimated costs for rebuilding and renovating the new leased areas are DKK [***] (confidential), with the landlord contributing DKK 10 million (excl. VAT) and financing an additional DKK 25,449,071 (excl. VAT) against a rent supplement.
• Annual rent (including rent supplement) for the Hellerup premises is DKK 25,161,356.15, payable quarterly in advance.
• The company's ownership in VISEN Pharmaceuticals decreased to 39.2% as of December 31, 2025, from 43.9% in 2024, following the IPO.
• The company's ownership in Eyconis Inc. was 33.2% as of December 31, 2025, down from 41.6% in 2024.
• A $100 million upfront fee from the Novo Nordisk collaboration was received in January 2025.
• The company repurchased 119,148 ADSs in March 2025, and the board authorized a new $120 million share repurchase program on January 9, 2026.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this filing positively due to robust revenue growth, successful product launches, and significant pipeline advancements, despite ongoing net losses and increased operating expenses. The strategic collaborations and strong clinical data underpin future growth potential.

Positives

• Achieved significant revenue growth in 2025, with total revenue increasing by 356.5 million EUR to 720.1 million EUR.
• YORVIPATH demonstrated strong commercial launch and uptake, contributing 477.4 million EUR in sales in 2025.
• SKYTROFA continued to show sales growth, reaching 206.2 million EUR in 2025.
• Net loss significantly improved by 150.1 million EUR in 2025 compared to 2024.
• Generated positive cash flows from operating activities of 53.9 million EUR in 2025, a substantial turnaround from a negative flow in 2024.
• Received a 100 million USD upfront payment in January 2025 from the exclusive worldwide license agreement with Novo Nordisk for TransCon technology in metabolic and cardiovascular diseases.
• VISEN Pharmaceuticals, a strategic collaboration partner, completed a successful IPO on the Hong Kong Stock Exchange in March 2025, resulting in a 35.7 million EUR non-cash gain.
• VISEN Pharmaceuticals received BLA approval for lonapegsomatropin (TransCon hGH) in China in January 2026.
• TransCon PTH (YORVIPATH) received FDA approval in August 2024 and Orphan Drug exclusivity in September 2024 for adult hypoparathyroidism, providing seven years of market exclusivity in the U.S.
• TransCon PTH (YORVIPATH) received EU regulatory approval in November 2023 and Orphan status in November 2023, providing ten years of market exclusivity.
• SKYTROFA received FDA approval in July 2025 for adult growth hormone deficiency (GHD), expanding its market.
• Positive top-line results from the Phase 2 New InsiGHTS Trial for TransCon hGH in children with Turner syndrome, showing improved growth similar to daily somatropin.
• Pivotal ApproaCH trial results for TransCon CNP in children with achondroplasia published in JAMA Pediatrics, demonstrating significantly higher annualized growth velocity and improved lower limb alignment and body proportionality.
• COACH Phase 2 trial showed combination therapy with TransCon CNP and TransCon hGH exceeded the 97th percentile of average-stature children for annualized growth velocity and improved achondroplasia-specific height Z-score by tripling efficacy compared to monotherapy.
• Maintains a robust intellectual property portfolio with over 465 granted patents and over 625 patent applications as of December 31, 2025.

Negatives

• Reported a net loss of 228.0 million EUR for the year ended December 31, 2025.
• Total equity presented a deficit of 162.8 million EUR as of December 31, 2025, worsening from a 105.7 million EUR deficit in 2024.
• Operating expenses increased by 163.3 million EUR in 2025, primarily due to global commercial expansion.
• Finance expenses increased significantly to 206.7 million EUR in 2025 from 100.0 million EUR in 2024, driven by remeasurement loss from financial liabilities and amortization charges.
• The company is substantially dependent on the success of its products and product candidates, with a limited commercial operating history.
• The long-term safety and efficacy of TransCon technologies and extended life in the body of product candidates are unknown, with limited human clinical data for systemic TransCon technologies.
• The company relies on single-source suppliers for critical drug products and components, posing a risk of supply disruption.
• The company may incur significant losses in the future, making it difficult to assess future viability.
• The company's estimated market opportunities for products are subject to numerous uncertainties and may prove inaccurate, potentially limiting future growth.
• The company is exposed to significant product liability risks inherent in drug development and commercialization.
• The company will need to significantly increase the size of its organization and may face difficulties managing growth and expanding operations successfully.
• The company incurs significant costs as a public company and management devotes substantial time to compliance initiatives.
• The Royalty Pharma Agreements place restrictions on operating and financial flexibility and could lead to default if covenants are not met.
• Exchange rate fluctuations, particularly between EUR, DKK, and USD, may adversely affect results of operations and financial condition, as the company does not currently hedge these risks.
• The UK's withdrawal from the EU (Brexit) may negatively affect global economic conditions, financial markets, and the company's business due to divergent regulatory requirements.
• The U.S. BIOSECURE Act could restrict the ability to purchase services or products from certain biotechnology companies of concern, potentially impacting foreign CROs and CMOs the company relies on.
• The Inflation Reduction Act (IRA) and other healthcare reforms in the U.S. and EU may make it more difficult and costly to obtain regulatory approvals, market products, and secure adequate reimbursement.
• The company is subject to global anti-corruption laws, and non-compliance could lead to criminal or civil liability.
• The company may be subject to claims of intellectual property misappropriation or challenges to patent ownership, which could be costly and time-consuming.

Risks

• Significant future losses may be incurred, making future viability difficult to assess.
• Additional financing may be required, and failure to obtain it on acceptable terms could delay or cease commercialization and product development.
• Substantial dependence on the success of products and product candidates, which may not achieve regulatory approval or successful commercialization.
• Clinical drug development is lengthy, expensive, and uncertain, with potential for substantial delays and non-predictive earlier trial results.
• Sales and marketing efforts may not be effective, hindering commercial success.
• Interim, top-line, and preliminary clinical trial data may change materially upon comprehensive review.
• Intense competition in the biotechnology and pharmaceutical industries from companies with greater resources or faster development cycles.
• Reliance on third-parties for manufacturing preclinical, clinical, and commercial supplies, including device components, with risks of failure to meet deadlines or regulatory requirements.
• Operating results may vary significantly from period to period and are difficult to predict.
• Dependence on certain single-source suppliers for parent drugs, drug products, and other components, with risks of loss or failure to supply.
• Adverse effects from health epidemics, pandemics, and other infectious disease outbreaks on operations, clinical trials, and supply chains.
• Unfavorable global and regional economic, political, health, climate, and other conditions and events (e.g., inflation, geopolitical conflicts, trade restrictions) could adversely affect business.
• Lengthy, time-consuming, and unpredictable regulatory approval processes by EMA, FDA, MHRA, and comparable authorities.
• Uncertainty of third-party payor coverage and reimbursement status for newly-approved products, potentially limiting market access and revenue generation.
• Risk of lawsuits for allegedly infringing intellectual property rights of third parties, leading to costly and time-consuming litigation and potential harm to business.
• Inability to successfully develop additional product candidates based on TransCon technologies.
• Undesirable side effects or other properties of products/product candidates could delay/prevent regulatory approval or result in negative consequences post-approval.
• Reliance on collaboration partners (e.g., VISEN, Teijin, Novo Nordisk, Eyconis) for development, regulatory approvals, marketing, and sales, with risks of non-performance or termination of agreements.
• Failure to obtain or maintain orphan designation benefits, including market exclusivity, for product candidates.
• Biological products may face competition sooner than anticipated due to biosimilar pathways.
• Significant regulation with respect to manufacturing, with risks that facilities may not meet requirements or supply demands.
• Operations involve hazardous materials, requiring compliance with environmental laws and regulations, which can be expensive and restrictive.
• Failure to comply with EU, FDA, and other local regulations related to promotion for unapproved uses could lead to criminal penalties, fines, or sanctions.
• Employees, contractors, and partners may engage in misconduct or improper activities, including noncompliance with regulatory standards.
• Non-compliance with global anti-corruption laws (e.g., FCPA) can lead to criminal/civil liability.
• Regulations related to conflict minerals may increase expenses and limit supply of certain metals.
• Failure to obtain regulatory approvals in non-U.S. jurisdictions would prevent marketing outside the U.S.
• Actual or perceived failures to comply with applicable data protection, privacy, and security laws (e.g., HIPAA, CCPA, GDPR, DSP) could adversely affect business.
• Legislative or regulatory healthcare reforms (e.g., ACA, IRA, OBBBA) may increase costs and make it harder to obtain approvals and market products.
• Disruptions at FDA and other government agencies due to funding shortages or staffing limitations could delay product development and approval.
• Intellectual property related to products and product candidates may be inadequate, impairing competitive ability.
• Changes to patent law could diminish the value of patents.
• Certain employees and patents are subject to German law, potentially requiring additional compensation for assigned patent rights.
• Failure to secure trademark registrations for commercial trade names could adversely affect business.
• Inability to enforce intellectual property rights throughout the world, particularly in countries with weaker protections.
• Use of artificial intelligence (AI) in business carries risks of inaccuracy, bias, intellectual property infringement, and data privacy issues.

Future Outlook

The company's Vision 2030 aims to achieve blockbuster status for multiple products and expand innovation, focusing on becoming the leading Endocrinology Rare Disease Company with over $5 billion in worldwide commercialization for TransCon PTH, hGH, and CNP. It also plans to create value in additional therapeutic areas like metabolic and cardiovascular diseases and ophthalmology through collaborations, pursuing TransCon product opportunities in over $5 billion indications, and obtaining accelerated approval in oncology with ongoing registrational trials. The lead program in the Novo Nordisk collaboration, a once-monthly TransCon Semaglutide product candidate, is on track to enter the clinic as anticipated.

Management Comments

• "We are applying our innovative TransCon technology platform to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients lives."
• "Guided by our core values of patients, science, and passion, we use our TransCon technologies to create new and potentially best-in-class therapies."
• "Our vision is to pursue TransCon product opportunities in >5B indications in other therapeutic areas and maximize value creation of these product opportunities through collaboration with therapeutic area market leaders."
• "We believe our approach to product innovation may reduce the risks associated with traditional drug development."
• "We believe that predictable release over time can improve treatment safety and efficacy, increase the likelihood of clinical development success, and provide intellectual property benefits."
• "We believe TransCon is well-suited to improve cancer treatments given the large number of validated targets with known limitations."
• "We believe our approach, if successfully developed, has the potential to improve the efficacy of systemically administered, clinically validated therapies while limiting adverse effects."

Industry Context

StockSavvy.ai notes that Ascendis Pharma's strong revenue growth, particularly from YORVIPATH, positions it favorably in the competitive rare disease market, especially given the discontinuation of Takeda's NATPARA. The expansion into adult GHD with SKYTROFA and the promising clinical data for TransCon CNP in achondroplasia demonstrate a robust pipeline addressing significant unmet medical needs. The strategic collaborations with Novo Nordisk for metabolic and cardiovascular diseases and Eyconis for ophthalmology reflect a broader industry trend of leveraging platform technologies through partnerships to de-risk development and expand market reach. The focus on long-acting therapies aligns with patient and physician demand for improved convenience and adherence, a key differentiator in crowded therapeutic areas. However, the increasing regulatory scrutiny on drug pricing and the evolving landscape of biosimilar competition remain significant industry-wide challenges.

Comparison to Industry Standards

• YORVIPATH's commercial success in hypoparathyroidism is notable, especially in the context of Takeda's NATPARA discontinuation, which creates a significant market opportunity. This positions YORVIPATH as a leading PTH replacement therapy, potentially surpassing previous market leaders in availability and patient access.
• SKYTROFA's growth in pediatric and adult GHD competes with established daily hGH products like Norditropin (Novo Nordisk), Humatrope (Eli Lilly), Genotropin (Pfizer), Zomacton (Ferring), and Omnitrope (Sandoz), as well as other once-weekly somapacitan (SOGROYA by Novo Nordisk) and somatrogon (NGENLA by Pfizer/OPKO Health). SKYTROFA's once-weekly administration and auto-injector design aim for best-in-class convenience and adherence, potentially outperforming daily injection regimens and addressing adherence challenges reported in studies like Kaplowitz et al. (2021).
• TransCon CNP for achondroplasia directly competes with BioMarin Pharmaceutical's daily VOXZOGO (vosoritide). The ApproaCH trial results, showing superior annualized growth velocity and improvements in lower limb alignment and body proportionality, suggest TransCon CNP could offer a differentiated profile, potentially addressing broader clinical needs beyond linear growth, which is a key area of unmet need in achondroplasia.
• The combination therapy of TransCon CNP and TransCon hGH in the COACH trial, demonstrating AGV exceeding the 97th percentile of average-stature children and tripling efficacy in achondroplasia-specific height Z-score compared to monotherapy, sets a high benchmark for treatment outcomes in this rare genetic condition, potentially offering a more comprehensive solution than existing monotherapies.
• The company's TransCon technology platform, designed for sustained release and predictable drug delivery, aims to overcome limitations of conventional prodrug and sustained release technologies, such as variable metabolic conversion rates seen in some competitors, by ensuring consistent active drug levels.

Management Changes

Corporate Governance

Legal Proceedings

• BioMarin Pharmaceutical Inc. initiated legal proceedings aimed at delaying or preventing patient access to TransCon CNP, including a case before the Unified Patent Court (UPC) in Munich related to alleged infringement against EP3175863 (the 863 patent).
• The European Patent Office (EPO) Technical Boards of Appeal revoked BioMarin's 863 patent in its entirety on October 16, 2025.
• As a consequence of the EPO revocation, the UPC dismissed the infringement case on December 29, 2025, with BioMarin agreeing to reimburse Ascendis for certain legal expenses.
• BioMarin filed a complaint with the U.S. International Trade Commission (ITC) related to alleged infringement of U.S. Reissue Patent No. 48,267, with a trial date set for April 2026.
• In response to the ITC action, Ascendis Pharma initiated legal action before the U.S. Northern District of California District Court, which has been stayed pending ITC proceedings.
• Ascendis Pharma instituted proceedings before the Danish Maritime and Commercial High Court, claiming entitlement to European patent applications EP21211450.8, EP25151367.7 and EP25175852.0, which are divisional applications of the revoked 863 patent; the EPO has granted a stay of proceedings.
• BioMarin submitted a Citizen Petition to the FDA on June 12, 2025, requesting the FDA refrain from approving any analog of human CNP as a treatment for achondroplasia until VOXZOGO's orphan-drug exclusivities expire; Ascendis Pharma submitted a response in September 2025, believing its NDA for TransCon CNP should not be impacted.
• Ascendis Pharma filed a petition before the Korean Intellectual Property Trial and Appeal Board (IPTAB) on October 21, 2025, for the invalidation of BioMarin's Korean patent KR2033680.

Related Party Transactions

• Employment agreements and grants of warrants, Restricted Stock Units (RSUs), and Performance Stock Units (PSUs) to Key Management Personnel (Board of Directors and Senior Management).
• Payment of fees for board tenure and board committee tenure to independent board members.
• Indemnification agreements with board members and senior management.
• Research and development services provided to VISEN Pharmaceuticals under Rights Agreements, with reimbursement from VISEN.
• Provision of clinical and commercial product supply to VISEN for use in Greater China under various supply agreements.
• Formation and launch of Eyconis, Inc. in January 2024, with Ascendis Pharma granting exclusive rights to develop and commercialize TransCon ophthalmology products globally in exchange for an equity position (33.2% ownership as of December 31, 2025).
• Provision of administrative and support services to Eyconis under a Transitional Services Agreement in 2024.
• Sale of laboratory and office inventory, materials, and assignment of certain contract manufacturers' contracts to Eyconis in 2024 under an Inventory Transfer Agreement and Material Transfer Agreement.
• Sublease of R&D and laboratory facilities to Eyconis, initially until December 2025, and extended until April 2030 in 2025.

Stakeholder Impact

• **Shareholders:** Experience dilution from future equity financings and exercise/conversion of warrants, RSUs, PSUs, and convertible notes. The $120 million share repurchase program could positively impact shareholder value. The significant net loss and equity deficit could concern investors, but strong revenue growth and positive operating cash flow provide optimism. Legal proceedings, especially those related to intellectual property, pose a risk to shareholder value.
• **Employees:** Benefit from warrant, RSU, and PSU incentive programs. The company's growth and expansion into new therapeutic areas offer career opportunities. Changes in senior management roles reflect internal promotions and new hires, indicating a dynamic work environment.
• **Customers (Patients & Healthcare Providers):** Benefit from the commercial availability of YORVIPATH and SKYTROFA, addressing unmet medical needs in hypoparathyroidism and GHD. The development of TransCon CNP for achondroplasia and combination therapies aims to provide improved treatment options. The auto-injector design for SKYTROFA enhances convenience.
• **Suppliers & Contract Manufacturers:** Continued reliance on third-party manufacturers and suppliers for critical materials and production, indicating ongoing business for these partners. However, single-source reliance poses risks if supply is interrupted.
• **Collaboration Partners (VISEN, Teijin, Novo Nordisk, Eyconis):** Benefit from exclusive license agreements and shared development efforts, expanding the global reach of TransCon technologies and products. VISEN's IPO and BLA approval in China demonstrate successful partnership outcomes. These partnerships are crucial for maximizing value creation in specific therapeutic areas and geographies.

Next Steps

• FDA to complete review of TransCon CNP NDA by PDUFA goal date of February 28, 2026.
• Continue commercialization of YORVIPATH and SKYTROFA in the U.S. and Europe Direct markets.
• Advance TransCon Semaglutide, the lead program in collaboration with Novo Nordisk, into the clinic.
• Provide median overall survival (OS) data for the TransCon IL-2 b/g cohort in the IL-Believe Trial in the second quarter of 2026.
• Initiate reACHin, a Phase 2 trial for TransCon CNP in infants with achondroplasia.
• Initiate a basket trial evaluating TransCon hGH for additional growth disorder indications (small for gestational age without catch-up growth; idiopathic short stature; SHOX deficiency).
• Continue investigating TransCon CNP, alone and in combination with TransCon hGH, for hypochondroplasia.
• Teijin to continue commercialization of YORVIPATH in Japan.
• VISEN Pharmaceuticals to continue development and commercialization of TransCon PTH and TransCon CNP in Greater China.
• Monitor and assess the possible impacts of existing and potential tariffs on operations, including the U.S. Reciprocal Tariffs.
• Address the U.S. International Trade Commission complaint related to alleged infringement of BioMarin's re-issue patent, with a trial date set for April 2026.
• Continue legal action before the Danish Maritime and Commercial High Court regarding entitlement to European patent applications EP21211450.8, EP25151367.7 and EP25175852.0.
• Implement the $120 million share repurchase program authorized by the Board.

Key Dates

Recommendation

Ascendis Pharma demonstrates strong underlying business momentum with significant revenue growth driven by successful commercialization of YORVIPATH and SKYTROFA. The substantial improvement in net loss and positive operating cash flow indicate a positive financial trajectory. The robust pipeline, particularly the promising clinical data for TransCon CNP in achondroplasia and the strategic collaborations with major pharmaceutical players like Novo Nordisk, de-risk future development and expand market opportunities. While the equity deficit and ongoing legal challenges are noted, the company's innovative TransCon technology platform and its ability to secure significant upfront payments from partnerships suggest strong long-term growth potential. The authorized share repurchase program further signals management's confidence in the company's valuation.

Keywords

Biopharmaceutical, Rare Disease, Endocrinology, Oncology, TransCon Technology, YORVIPATH, SKYTROFA, Hypoparathyroidism, Growth Hormone Deficiency, Achondroplasia, Clinical Trials, Regulatory Approval, Commercialization, SEC Filing, Financial Results, Biotech, Pharmaceutical, Drug Development, Intellectual Property, Partnerships, Novo Nordisk, VISEN Pharmaceuticals, Eyconis, Teijin